[Respiratory syncytial virus infections and preventive options].
Moll
H A
HA
de Groot
R
R
D000911:Antibodies, Monoclonal / Q000191:economics* / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000191:economics* / Q000494:pharmacology / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D006760:Hospitalization / Q000191:economics; D006801:Humans; D007223:Infant; D015337:Multicenter Studies as Topic; D009426:Netherlands / Q000453:epidemiology; D000069455:Palivizumab; D011358:Product Surveillance, Postmarketing; D018357:Respiratory Syncytial Virus Infections / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control*; D014481:United States
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab